clinical trial · NCT00833521
Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions
Teva Pharmaceuticals USA·phase1·completed·n = 38
HealthyZolpidem 10 mg tabletsAMBIEN® 10 mg tablets
brief summary
The objective of this study is to compare the relative bioavailability of Zolpidem tartrate 10 mg tablets (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of AMBIEN® tablets(G.D. Searle \& Co.) in healthy, adult, non-smoking subjects under fasting conditions.
started
Feb 1, 2002
primary completion
Feb 1, 2002
completion
Feb 1, 2002
last updated
Aug 21, 2024
detailed description
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
official title
A Relative BioAvailability Study of Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol